Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.60 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.60 |
| ▸ | APP | P05067 | 3/20 | 0.60 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.60 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.60 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.60 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.60 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.60 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.60 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | PRNP | P04156 | 1/20 | 0.60 |
| ▸ | NQO2 | P16083 | 1/20 | 0.60 |
| ▸ | MTOR | P42345 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL5071916 | 0.93 | KDM4E (0.64) | KCNH2CHRM2CHRM1ADRA2CAPP | |
| SCHEMBL3229048 | 0.92 | CDK1 (0.66) | KCNH2CHRM2CHRM1ADRA2CAPP | |
| SCHEMBL1695452 | 0.85 | CHRM2 (0.43) | KCNH2CHRM2CHRM1ADRA2CAPP | |
| SCHEMBL3454269 | 0.85 | CHRM2 (0.43) | KCNH2CHRM2CHRM1ADRA2CAPP | |
| SCHEMBL1550998 | 0.83 | KDM4E (0.58) | KCNH2CHRM2CHRM1ADRA2CAPP | |
| SCHEMBL15475876 | 0.82 | CHKA (0.58) | KCNH2CHRM2CHRM1ADRA2CAPP | |
| SCHEMBL25551631 | 0.82 | CHRM2 (0.66) | KCNH2CHRM2CHRM1ADRA2CAPP | |
| SCHEMBL1147504 | 0.82 | NR4A2 (0.54) | KCNH2CHRM2CHRM1ADRA2CAPP | |
| SCHEMBL6388962 | 0.81 | CHKA (0.57) | KCNH2CHRM2CHRM1ADRA2CAPP | |
| SCHEMBL1695271 | 0.81 | HRH3 (0.60) | SIGMAR1SLC6A2HRH3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581167-A4 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE AND TARDIVE DYSKINESIAS | ALPHA RES GROUP LLC (US) | 2008-10-29 | — | — | EP | claimed |
| JP-2006514917-A | — | — | 2006-05-18 | — | — | JP | claimed |
| EP-1581167-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE AND TARDIVE DYSKINESIAS | Alpha Research Group, LLC (US) | 2005-10-05 | — | — | EP | claimed |
| WO-2004043365-A2 | METHOD FOR TREATMENT OF PREMATURE EJACULATION IN HUMANS | AZAYA THERAPEUTICS, INC. (US) | 2004-05-27 | — | — | WO | claimed |
| WO-2004004660-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON’S DISEASE AND TARDIVE DYSKINESIAS | ALPHA RESEARCH GROUP, L.L.C. (US) | 2004-01-15 | — | — | WO | claimed |
| WO-2026102297-A1 | ANTIBODY OLIGONUCLEOTIDE CONJUGATES FOR TREATING DISEASE | Fulcrum Therapeutics, Inc. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4735602-A2 | COMPOSITIONS AND METHODS OF USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES ABSTRACT | Atrium Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025006639-A2 | COMPOSITIONS AND METHODS OF USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES ABSTRACT | AVIDITY BIOSCIENCES, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| EP-4401792-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | Avidity Biosciences, Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| WO-2023043953-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | AVIDITY BIOSCIENCES, INC. (US) | 2023-03-23 | — | — | WO | disclosed |
| EP-4126066-A1 | COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY | Avidity Biosciences, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| EP-4121063-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | Avidity Biosciences, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| WO-2003039552-A1 | COMBINATION OF PDE4 OR PDE3/4 INHIBITOR AND AN ANTI-RHEUMATIC DRUG | ALTANA PHARMA AG (DE) | 2003-05-15 | — | — | WO | disclosed |
| EP-1261340-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE | Alpha Research Group, LLC (US) | 2002-12-04 | — | — | EP | disclosed |
| WO-2001003649-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE | ALPHA RESEARCH GROUP, LLC (US) | 2001-01-18 | — | — | WO | disclosed |
| EP-0659082-A1 | USE OF CYTOCHROME P450 INHIBITORS FOR INHIBITING THE METABOLISM OF NITROGEN SUBSTITUTED ACRIDINE | WARNER-LAMBERT COMPANY (US) | 1995-06-28 | — | — | EP | disclosed |
| WO-1994005296-A2 | USE OF CYTOCHROME P450 INHIBITORS FOR INHIBITING THE METABOLISM OF NITROGEN SUBSTITUTED ACRIDINE | WARNER-LAMBERT COMPANY (US) | 1994-03-17 | — | — | WO | disclosed |
| EP-0583439-A1 | ANTIMALARIAL SYNERGISTIC COMPOSITIONS CONTAINING BENFLUMETOL | Novartis AG (CH) | 1994-02-23 | — | — | EP | disclosed |
| WO-1993015727-A1 | ANTIMALARIAL SYNERGISTIC COMPOSITIONS CONTAINING BENFLUMETOL | CIBA-GEIGY AG (CH) | 1993-08-19 | — | — | WO | disclosed |
| EP-0214101-A2 | Use of iron(III) chelators of the type desferrioxamine-B and desferriferrithiocine in the treatment of malaria | CIBA-GEIGY AG (CH) | 1987-03-11 | — | — | EP | disclosed |